Skinner M S, Seckinger D
Ann Clin Lab Sci. 1979 Jul-Aug;9(4):347-52.
The advent of the radioimmunoassay of Beta subunit chorionic gonadotropin (BhCG) has eliminated a major problem in following the patient with gestational trophoblastic neoplasia (GTN). Whole hCG cross reacts with luteinizing hormone (hLH) causing difficulties when GTN patient titers fall to levels coincidental with pituitary levels of hLH. The use of the Beta subunit of hCG in radioimmunoassay has eliminated this problem because there is essentially no cross reaction between the B-subunit of the hCG and hLH. A review of the use of this sensitive assay in the management of patients with GTN is presented.
β-亚基绒毛膜促性腺激素（BhCG）放射免疫测定法的出现，消除了随访妊娠滋养细胞肿瘤（GTN）患者时的一个主要问题。完整的人绒毛膜促性腺激素（hCG）与促黄体生成素（hLH）发生交叉反应，当GTN患者的滴度降至与垂体hLH水平一致时就会产生困难。在放射免疫测定中使用hCG的β亚基消除了这个问题，因为hCG的β亚基与hLH之间基本没有交叉反应。本文对这种灵敏测定法在GTN患者管理中的应用进行了综述。
